Pentosan Polysulfate
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
- Pentosan Polysulfate
- Pentosan Polysulfate: From Interstitial Cystitis to Primary Release Disorder of Platelets
Pentosan Polysulfate: From Interstitial Cystitis to Primary Release Disorder of Platelets
One-Sentence Summary
Pentosan polysulfate is a semi-synthetic sulfated polysaccharide, originally used to treat interstitial cystitis. The TxGNN model predicts it may be effective for primary release disorder of platelets, but no clinical trials and no publications currently support this direction. The prediction is computational only and, on mechanistic grounds, raises a safety concern.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Interstitial cystitis |
| Predicted New Indication | Primary release disorder of platelets |
| TxGNN Prediction Score | 99.71% |
| Evidence Level | L5 |
| US Market Status | Cancelled only (no currently valid license) |
| Number of NDAs | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, pentosan polysulfate is a semi-synthetic sulfated polysaccharide with heparin-like, weak anticoagulant activity and effects on coagulation and fibrinolysis. Its efficacy in interstitial cystitis is the basis of its original use.
The link to the predicted indication is purely computational. A drug acting on coagulation and fibrinolysis could plausibly touch platelet or hemostatic pathways. However, its anticoagulant activity would more likely worsen bleeding tendency in a platelet function disorder than treat it. The high score may reflect network proximity to hemostasis-related genes rather than a true therapeutic rationale.
The same pattern appears in the other top predictions:
- Glanzmann thrombasthenia (score 99.65%): caused by deficiency or dysfunction of integrin alphaIIb-beta3, which impairs platelet aggregation. Pentosan polysulfate has no known action that restores this receptor.
- Pseudo-von Willebrand disease (score 99.62%): a gain-of-function defect in platelet GPIb-alpha. A theoretical interaction with glycosaminoglycan-binding or VWF-related pathways exists, but there is no evidence of benefit.
All three predictions are likely graph-proximity artifacts.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| NDA020193 | ELMIRON (Janssen Pharmaceuticals, Inc.) | Capsule, gelatin coated (oral) | Not listed in the data (status: cancelled) |
Safety Considerations
- Disease-level contraindication signals (knowledge graph, not label text): liver disease, gallbladder disease, thrombocytopenia, blood coagulation disease, hemophilia, and heparin-induced thrombocytopenia. These overlap strongly with the predicted bleeding and platelet disorders, so the proposed use is in direct tension with them.
- Drug Interactions: 58 interactions were identified, and the 20 listed in the data are all rated Moderate. Most involve agents that affect bleeding or clotting, which fits the drug’s anticoagulant-like properties:
- Antiplatelet agents: acetylsalicylic acid, clopidogrel, cilostazol, dipyridamole, abciximab, cangrelor
- Anticoagulants: warfarin, apixaban, edoxaban, betrixaban, dalteparin, bivalirudin, antithrombin III
- Thrombolytics and related agents: alteplase, anistreplase, defibrotide, caplacizumab
- Radiolabelled antibodies: ibritumomab tiuxetan, tositumomab (including I-131)
Please refer to the package insert for label warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score, with no trials or literature. The drug’s anticoagulant-like activity and the knowledge-graph contraindications (coagulation disease, hemophilia, thrombocytopenia) suggest a risk of worsening bleeding rather than benefit. The only US license is cancelled.
To proceed, the following is needed:
- Package insert warnings and contraindications, which are a blocking gap for safety screening
- Detailed mechanism of action data
- Preclinical or mechanistic evidence that the drug affects platelet release or function in a beneficial direction
- A bleeding-risk assessment for patients with platelet function disorders
- Clarification of regulatory and route-of-administration feasibility, given the cancelled license
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.